EUVIMEDEUVIMED entdecken
Crossref

Risk factors for short-term prognosis of end-stage liver disease complicated by invasive pulmonary aspergillosis

Weiyan Yu, Ying Xiao, Yue Luo, Yangyang Hu, Ru Ji, Wei Wang, Zhinian Wu, Zeqiang Qi, Tingyu Guo, Yadong Wang, Caiyan Zhao

European Journal of Clinical Microbiology & Infectious Diseases · 2024

DOI: 10.1007/s10096-024-04775-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2024. Verfasst von Weiyan Yu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease, the Hebei Medical University Third Hospital, No. 139, Ziqiang Road, Shijiazhuang, 050051, Hebei, China. Hauptthemen laut MEDLINE: Invasive Pulmonary Aspergillosis, End Stage Liver Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Hebei Provincial Key Research Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIM: Patients with end-stage liver disease (ESLD) are susceptible to invasive pulmonary aspergillosis (IPA). This study aimed to investigate the risk factors affecting the occurrence and short-term prognosis of ESLD complicated by IPA. METHODS: This retrospective case-control study included 110 patients with ESLD. Of them, 27 ESLD-IPA received antifungal therapy with amphotericin B (AmB); 27 AmB-free-treated ESLD-IPA patients were enrolled through 1:1 propensity score matching. Fifty-six ESLD patients with other comorbid pulmonary infections were enrolled as controls. The basic features of groups were compared, while the possible risk factors affecting the occurrence and short-term outcomes of IPA were analyzed. RESULTS: Data analysis revealed invasive procedures, glucocorticoid exposure, and broad-spectrum antibiotic use were independent risk factors for IPA. The 54 patients with ESLD-IPA exhibited an overall treatment effectiveness and 28-d mortality rate of 50.00% and 20.37%, respectively, in whom patients treated with AmB-containing showed higher treatment efficacy than patients treated with AmB-free antifungal regimens (66.7% vs. 33.3%, respectively, χ2 = 6.000, P = 0.014). Multivariate logistic regression analysis revealed that the treatment regimen was the only predictor affecting patient outcomes, with AmB-containing regimens were 4.893 times more effective than AmB-free regimens (95% CI, 1.367-17.515; P = 0.015). The only independent predictors affecting the 28-d mortality rate were neutrophil-to-lymphocyte ratio and IPA diagnosis (OR = 1.140 and 10.037, P = 0.046 and 0.025, respectively). CONCLUSIONS: Glucocorticoid exposure, invasive procedures, and broad-spectrum antibiotic exposure increased the risk of IPA in ESLD patients. AmB alone or combined with other antifungals may serve as an economical, safe, and effective treatment option for ESLD-IPA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Invasive Pulmonary AspergillosisEnd Stage Liver DiseaseHumansAntifungal AgentsRetrospective StudiesCase-Control StudiesGlucocorticoidsAmphotericin BPrognosisRisk FactorsAnti-Bacterial Agents

Stichwörter der Autor:innen

Amphotericin BEnd-stage liver diseaseInvasive pulmonary aspergillosisPrognostic modelRisk factor

Substanzen

Antifungal AgentsGlucocorticoidsAmphotericin BAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Infectious Disease, the Hebei Medical University Third Hospital, No. 139, Ziqiang Road, Shijiazhuang, 050051, Hebei, China.
  • Hebei Clinical Medical Research Center of Infectious Diseases, Shijiazhuang, 050051, China.
  • Public Health Clinical Center of Chengdu, Chengdu, 610011, China.
  • Department of Infectious Disease, the Hebei Medical University Third Hospital, No. 139, Ziqiang Road, Shijiazhuang, 050051, Hebei, China. wangyadong8060@126.com.
  • Hebei Clinical Medical Research Center of Infectious Diseases, Shijiazhuang, 050051, China. wangyadong8060@126.com.
  • Department of Infectious Disease, the Hebei Medical University Third Hospital, No. 139, Ziqiang Road, Shijiazhuang, 050051, Hebei, China. zhaocy2005@163.com.

Förderung

  • Hebei Provincial Key Research Projects

Zitieren

APA

Yu, W., Xiao, Y., Luo, Y., Hu, Y., Ji, R., Wang, W., Wu, Z., Qi, Z., Guo, T., Wang, Y., & Zhao, C. (2024). Risk factors for short-term prognosis of end-stage liver disease complicated by invasive pulmonary aspergillosis. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-024-04775-1

Vancouver

Yu W, Xiao Y, Luo Y, Hu Y, Ji R, Wang W, et al. Risk factors for short-term prognosis of end-stage liver disease complicated by invasive pulmonary aspergillosis. European Journal of Clinical Microbiology & Infectious Diseases. 2024. doi:10.1007/s10096-024-04775-1

BibTeX
@article{Yu2024,
  author = {Yu, Weiyan and Xiao, Ying and Luo, Yue and Hu, Yangyang and Ji, Ru and Wang, Wei and Wu, Zhinian and Qi, Zeqiang and Guo, Tingyu and Wang, Yadong and Zhao, Caiyan},
  title = {Risk factors for short-term prognosis of end-stage liver disease complicated by invasive pulmonary aspergillosis},
  journal = {European Journal of Clinical Microbiology & Infectious Diseases},
  year = {2024},
  doi = {10.1007/s10096-024-04775-1}
}
Kostenlos starten →